A Phase I Study of Positron Emission Tomography With 89Zr-Df-IAB22M2C in Patients With Selected, Metastatic Solid Malignancies (Non Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma Head and Neck, Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs IAB 22M2C (Primary)
- Indications Cancer; Graft-versus-host disease
- Focus Adverse reactions; Diagnostic use
- Sponsors ImaginAb Inc
- 02 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
- 02 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 May 2018.
- 04 Apr 2017 Status changed from planning to recruiting.